Publications by authors named "Carballada Gonzalez Francisco"
Background: Efficacy of allergen immunotherapy is dose-dependent; however, high doses of allergen may imply a greater risk of adverse reactions.
Objective: To assess the safety and tolerability of subcutaneous immunotherapy (SCIT) with mixtures of mite allergen extracts, Dermatophagoides pteronyssinus/Blomia tropicalis (Dpt/Bt) and Dermatophagoides pteronyssinus/Lepidoglyphus destructor (Dpt/Ld) at maximum concentrations, in adult patients with allergic rhinitis or rhinoconjunctivitis, and controlled allergic asthma due to a clinically relevant sensitisation to these mites.
Methods: An open-label, noncontrolled, nonrandomised, phase IIb clinical trial was carried out in three hospitals in Spain between September 2014 and May 2018.
Real-World Safety and Efficacy Clinical Data of an Improved Allergen-Specific Immunotherapy Product for the Treatment of Bee Venom Allergy.
Vaccines (Basel)
May 2023
The aim of this study is to explore the safety and efficacy of bee venom immunotherapy without HSA, in real-life patients. Methods: This is an observational retrospective study developed in seven hospitals in Spain, where patients treated with this immunotherapy were included. They gathered the protocol used to initiate the immunotherapy, adverse reactions, field re-stings, and the patient clinical data (clinical history, biomarkers, and skin prick test).
View Article and Find Full Text PDFFactors that determine the loss of control when reducing therapy by steps in the treatment of moderate-severe asthma in standard clinical practice: A multicentre Spanish study.
Rev Clin Esp (Barc)
March 2020
Article Synopsis
- The study focused on identifying factors that contribute to the failure of asthma treatment step-down in patients with moderate to severe asthma who were on a combination therapy of inhaled glucocorticoids and long-acting beta agonists.
- Results showed that 41.7% of patients experienced step-down failure, with significant factors including older age, multiple comorbidities, severity of asthma, and a short duration of previous asthma control.
- The conclusion emphasizes that successful step-down is more likely when patients have maintained asthma control for over 6 months, suggesting that careful consideration is needed before adjusting treatment.